We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Adaptive Biotechnologies Corp is a biotechnology business with stocks listed in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$8.24 – an increase of 6.32% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
| 52-week range | US$5.955 - US$43.397 |
|---|---|
| 50-day moving average | US$8.1275 |
| 200-day moving average | US$20.1999 |
| Target price | US$15.3 |
| PE ratio | N/A |
| Dividend yield | US$0 (0%) |
| Earnings per share (TTM) | US$-1.626 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $8.24
| 1 week (2022-06-23) | -5.29% |
|---|---|
| 1 month (2022-05-26) | 8.85% |
| 6 months (2021-12-30) | -70.91% |
| 1 year (2021-06-30) | -79.83% |
|---|---|
| 2 years (2020-06-30) | -82.97% |
| 3 years (2019-06-28) | -82.94% |
| Revenue TTM | US$154.5 million |
|---|---|
| Gross profit TTM | US$91 million |
| Return on assets TTM | -14.94% |
| Return on equity TTM | -35.88% |
| Profit margin | -148.44% |
| Book value | 3.891 |
| Market capitalisation | US$1.2 billion |
TTM: trailing 12 months
We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as US$5.955 up to US$43.397. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 1.0667. This would suggest that Adaptive Biotechnologies's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
Steps to owning and managing The Lottery Corporation shares.
